Adicet Bio says prula-cel Phase 1 lupus study shows 54% DORIS remission at 12 months
Company says patients also showed sustained disease control, broad discontinuation of immunosuppressants and steroid tapering.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.